Main results
We identified three trials. One randomised 83 patients with emotional disturbance after stroke to fluoxetine or placebo. After correcting for differences in fatigue severity at baseline, there was no significant difference in fatigue between groups at follow up. The second trial randomised 31 women with subarachnoid haemorrhage to tirilazad or placebo, of whom 18 were available for follow up. There was no difference in fatigue between the two groups. The third trial investigated a chronic disease self-management programme in 1150 patients with chronic diseases, of whom 125 had had a stroke. There was no difference in fatigue at follow up between the treatment and control in the subgroup with stroke.
Authors' conclusions
There is insufficient evidence available to guide the management of fatigue after stroke. Further trials are required.
P L A I N L A N G U A G E S U M M A R Y

Interventions for post-stroke fatigue
Fatigue is common and distressing after stroke. This review found three small, randomised controlled trials that recruited a total of 239 people who had had a stroke to three different treatments (two different drug treatments and one chronic disease self-management programme). At follow up, there was no difference in fatigue levels between the patients who received the active treatments and those who received usual care or placebo. However, the trials were too small to provide firm conclusions and further trials are required.
B A C K G R O U N D Description of the condition
Stroke is a major cause of long-term disability. Over the past few years, evidence has been emerging that fatigue is a common, longterm problem after stroke (Ingles 1999) . It is distressing to patients (van der Werf 2001), and may predict death (Glader 2002) . Estimates of the prevalence of fatigue after stroke range from 16% (Glader 2002) to 70% (Carllson 2003; Leegard 1983) , depending on the population studied (e.g. inpatients or community patients, time since stroke, severity of stroke), whether people with depression were included or excluded, and how fatigue was identified (e.g. single question or fatigue scales). Normal fatigue can be defined as a state of general tiredness that is a result of overexertion and can be ameliorated by rest (De Groot 2003) . Abnormal (or pathological) fatigue is a state characterised by weariness unrelated to previous exertion levels and is usually not ameliorated by rest (De Groot 2003) . Recently, diagnostic criteria and an associated structured interview have been developed to identify which stroke patients have clinically significant fatigue (Lynch 2007). . Fatigue may have an underlying biological mechanism; one small study of 38 participants found a relationship with plasma glutamate/glutamine ratio (Syed 2007). In cancer patients, fatigue may be related to cortisol dysregulation (Bower 2005) . The relationship between cortisol dysregulation and fatigue after stroke has not been studied. Another interesting hypothesis is that fatigue may be associated with physical deconditioning, which is common after stroke (Saunders 2004), but the single study which has investigated the relationship between fatigue and fitness found no association (Michael 2006).
Description of the interventions
Since fatigue following stroke may have several causative factors, there are a number of potential interventions, in combination or alone, that may help. Possible interventions include pharmacological treatments (e.g. antidepressants, stimulants), psychologi-cal treatments (e.g. cognitive behavioural therapy, counselling) or physical treatments, such as graded exercise. It is currently not clear which approach may help to reduce the severity of fatigue following stroke. Thus, this review aimed to identify any intervention used to treat fatigue after stroke, where assessment of fatigue was a primary or secondary outcome.
How the interventions might work
Without being certain about the causes of fatigue, the mechanisms by which any intervention may work are unclear. We could hypothesise that exercise, by means of reversing physical deconditioning, might reduce fatigue; that psychological treatments might improve mood and so reduce fatigue; or that drugs, such as antidepressants, could increase levels of brain serotonin, which might, in theory, also reduce fatigue.
Why is it important to do this review?
Currently there is uncertainty about how to manage fatigue after stroke. In clinical practice, physicians may assess for co-existing, treatable conditions such as anaemia, depression, hypothyroidism and infection, but often these conditions are not present. There are currently no published systematic reviews of interventions for fatigue after stroke. Thus, this review is broad, as we wished to identify any intervention that had been used to treat fatigue after stroke, and so we decided to include trials where fatigue was a primary or secondary endpoint.
O B J E C T I V E S
The objectives of this systematic review were to determine:
1. whether any treatment for fatigue after stroke reduces the proportion of patients with fatigue, or the severity of fatigue, or both;
2. the effect of treatment on health-related quality of life, disability, dependency and death, and whether such treatments are cost effective.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials (RCTs) in patients with a clinical diagnosis of stroke. We included trials that compared an intervention for fatigue plus usual care versus usual care alone. We also included studies that compared the effect of different interventions, or different doses of interventions, where the interventions were aimed at treating fatigue. We included trials where fatigue was pre-specified as either a primary or secondary outcome. There were no language restrictions. We included published and unpublished trials.
Types of participants
We included adult men and women aged 18 years and over (with no upper age limit). Stroke was defined by clinical criteria, and included all pathological subtypes. We included patients with subarachnoid haemorrhage. We included any means of diagnosis or assessment of fatigue.
Types of interventions
We included any intervention used with the intention of treating fatigue as either a primary or secondary outcome, including pharmacological and non-pharmacological treatments in combination or alone. If the intervention was applied as a component of a complex intervention, the comparison was usual care alone versus usual care plus the complex intervention. We expected that the types of interventions would include antidepressants, other pharmacological agents, exercise, counselling, and cognitive behavioural therapy (CBT), but we did not limit the review to these types of interventions only.
Types of outcome measures
The primary outcome for this review was fatigue, measured either as the proportion of patients with fatigue or the severity of fatigue, or both. Examples of possible assessment measures included, but were not limited to:
• Fatigue Severity Scale (Krupp 1989);
• visual analogue scale for fatigue severity;
• fatigue self-reported questionnaire;
• energy/fatigue scale from the Medical Outcomes Study.
The secondary outcomes were health-related quality of life (assessed by, for example, Short Form 36), disability (e.g. Barthel score), dependence (e.g. Modified Rankin scale), cost effectiveness, and death. 
Search methods for identification of studies
Data collection and analysis
Selection of studies
All titles and abstracts from each search were scrutinised for relevance by the review author who performed the search (please see above). We excluded obviously irrelevant references and obtained full references for potentially relevant studies. A second review author scrutinised the potentially relevant studies and determined whether they fulfilled the inclusion criteria (GM scrutinised potentially relevant studies identified by EM; AP scrutinised studies identified by LS; LS scrutinised studies identified by AP; and EM scrutinised studies identified by GM). We resolved any discrepancies about whether or not the studies fulfilled the inclusion criteria by referring to the original paper and through discussion.
Contact with authors
We contacted authors of the included trials and the ongoing trials to obtain information that was not included in the trial reports, and to enquire about unpublished or ongoing trials.
Data extraction and management
Two review authors independently extracted data from the included studies and recorded the information on a data extraction form. GM and EM independently extracted data from the studies obtained from the MEDLINE and EMBASE database searches, AP and LS independently extracted data from the study identified through searching the PEDro database. We collected information regarding the age, sex and numbers of participants, the study setting, the pathological subtypes and severity of strokes included, the time since stroke onset, the intervention -including its duration, primary and secondary outcome measures, criteria used to diagnose fatigue, the assessment methods of fatigue at baseline and follow up, and the intervals at which the outcome measures were recorded. We extracted the data onto paper forms. We had intended to use an electronic database to manage our data, but as there were only three included trials, it was more practical to manage the data using the paper forms.
Study quality
Assessment of risk of bias in included studies
We assessed the quality of studies by noting whether allocation was concealed, whether the analysis was by intention-to-treat, and whether there was blinding of outcome assessment. For concealment of allocation, we distinguished between trials that were adequately concealed (central randomisation at a site remote from the study, computerised allocation in which records are in a locked readable file that can be assessed only after entering patient details, the drawing of opaque envelopes), inadequately concealed (open list or table of random numbers, open computer systems, drawing of non-opaque envelopes) and unclear (no information in the report or authors did not respond to our request for information or were unable to provide it).
We defined 'intention-to-treat' as present if two criteria were fulfilled: (1) all trial participants were analysed in the groups to which they were randomised regardless of which (or how much) treatment they actually received, and regardless of other protocol irregularities, such as ineligibility; and (2) all participants were included regardless of whether their outcomes were actually collected. For trials that did not fulfil these two criteria, we determined whether an 'available-case analysis' or a 'treatment-received analysis' had been performed. For blinding we distinguished between trials in which the main outcome was measured by an assessor who was blind to treatment allocation, and those in which it was measured by the participants themselves or by a non-blinded assessor.
Assessment of heterogeneity
We intended to measure heterogeneity using I 2 .
Measures of treatment effect
We undertook a narrative review of all studies. When trials used a number of different tools to assess fatigue, we included the main outcome measure as specified by the study authors. For instances where the study authors used a number of different outcome measures without pre-specifying the main one, we specified the main outcome measure in order of preference as follows: a dichotomous measure of fatigue designed specifically for stroke (e.g. a case definition) (Lynch 2007), a generic dichotomous measure for fatigue that has been tested in stroke, a generic dichotomous measure of fatigue not tested in stroke, a scale designed specifically for measuring fatigue severity after stroke, one of the generic fatigue scales tested in stroke (Mead 2007 ), a generic fatigue scale not previously tested in stroke. If interventions included different doses (for example, high-intensity exercise versus low-intensity exercise versus control), we had intended combining the results of the various active treatment arms in a trial or, where that was not possible, we had intended to divide the control group into several parts, one to go with each active arm, so that patients were not double counted. We intended to calculate relative risks (and 95% confidence intervals) for dichotomous outcome (i.e. fatigue or no fatigue) and standardised mean differences for continuous data, ensuring that, should some scales increase with fatigue severity whilst others decrease, we would multiply the mean values from one set of trials by -1 (or alternatively subtract the mean from the maximum possible value for the scale). We anticipated that some outcome scales would include individual questions relating to fatigue. We intended to use only the data for total scale scores, unless the individual questions had been validated as measures of fatigue. We intended to perform pooled analyses for each intervention using the Cochrane Review Manager software, RevMan 5.0 ( RevMan 2008), and using a random-effects model, but the interventions were too diverse for data to be combined.
Sub-group analysis and investigation of heterogeneity
We intended to explore heterogeneity by subgroup analyses. These were:
1. source of participants, community volunteers versus clinical patients;
2. type of treatment; 3. duration of treatment; 4. length of follow up. We intended to use an established method for subgroup analyses (Deeks 2001).
Sensitivity analysis
We intended to explore methodological heterogeneity through the use of sensitivity analysis.
1. Allocation concealment: we intended to re-analyse the data including only those trials with adequate allocation concealment.
2. Intention-to-treat analysis: we intended to re-analyse the data including only those trials with intention-to-treat analyses.
3. Blinding of outcome assessment: we intended to re-analyse the data including only those trials with blinding of outcome assessment.
4. Publication type (peer-reviewed journal, conference abstract/proceedings, doctoral dissertation): we intended to reanalyse the data including only those trials from peer-reviewed journals.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies.
Results of search
One review author (EM) scrutinised 4231 titles and another review author (GM) scrutinised 241 titles. Between them, both authors retrieved 17 full papers. Of these 17 papers, there was one obviously irrelevant randomised controlled trial (RCT) (eperisone versus physiotherapy for muscle tone), one case report, seven observational studies, six (non-systematic) review articles, and two RCTs which met our inclusion criteria (Choi-Kwon 2007; Ogden 1998). Another review author (LS) scrutinised 83 titles and retrieved seven full papers including five reviews and two obviously irrelevant RCTs. This author scrutinised a further 355 titles identified from citation searching. A fourth review author (AP) scrutinised 187 titles and retrieved five full papers. Of these, two were obviously irrelevant and three 
Included studies
Three completed trials met our inclusion criteria. Choi Kwon et al evaluated the therapeutic effect of fluoxetine on fatigue and other emotional disturbances in a placebo controlled, double-blind trial in 83 outpatients with post-stroke emotional disturbances at a mean of 14 months after stroke onset (ChoiKwon 2007). The presence of fatigue or the severity of fatigue were not selection criteria for inclusion in the study. Participants were assigned to receive either 20 mg of fluoxetine a day or placebo for three months. Post-stroke fatigue was evaluated by the fatigue severity scale (FSS) and visual analogue scale (VAS) at baseline, three months and six months after the start of treatment. There were two primary endpoints: the mean VAS scores and the mean FSS scores. The secondary endpoints were the per cent changes in VAS scores and FSS scores between baseline and follow up. The participants' mean age was 56.4 years in the placebo arm and 57.2 years in the drug-treated arm. Diagnoses included both ischaemic and haemorrhagic strokes. Ogden et al assessed the effectiveness of giving tirilazad mesylate (a hypothesised neuroprotective agent), in women with subarachnoid haemorrhage on neuropsychological and psychosocial outcomes including fatigue (Ogden 1998). Thirty-one participants were randomly assigned to receive either 100 ml of placebo (vehicle, i.e. the substance in which a drug is administered) or 100 ml of 1.5 mg/ml tirilazad mesylate for 10 consecutive days after subarachnoid haemorrhage. The presence of fatigue was not recorded at baseline. Of these 31 participants, 18 were still alive and were capable of, and consented to, being interviewed three months later. This interview included a two-hour battery of neuropsychological tests, a semi-structured interview and a questionnaire performed by a neurosurgeon. In the semi-structured interview, participants were asked whether they were suffering from fatigue or sleepiness that was much worse than before their subarachnoid haemorrhage -if they answered 'yes' then the interviewer explored this with further questioning and participants were asked to provide specific examples. Participants' responses to questioning were analysed as a 'yes or no' to debilitating fatigue based on a subjective opinion of the interviewer. The mean age of participants was 45.1 years for the drug-treated group and 49.7 for the placebo arm. Lorig et al evaluated a chronic disease self-management programme (CDSMP) on health status, health care utilisation and self-efficacy outcomes (Lorig 2001). The trial recruited 1140 community-dwelling participants with a mean age of 65 years from various forms of public advertising over a four-and-a-half-year period. Participants had diagnoses of chronic lung disease, heart disease, stroke ('completed cerebrovascular accident with neurologic handicap and normal mentation') or chronic arthritis. Participants were sent a questionnaire at baseline and randomly assigned to immediate CDSMP or were put on a waiting list to receive CDSMP after the six-month follow-up assessments ('waitlist' control group). There were 125 patients in the subgroup with stroke, of whom 67 were allocated to CDSMP and 58 to 'wait list' control. Patients allocated immediate CDSMP participated in seven weekly sessions, each lasting two-and-a half hours, in community centres where they were taught CDSMP by peer leaders. This included teaching about exercise programmes, the use of cognitive symptom management techniques, nutritional change, fatigue and sleep management, use of community resources, use of medications, dealing with emotions of fear, anger and depression, communication with others, problem solving, and decision making. The programme was implemented through a 'self efficacy theory', the process of which was documented in a manual, and all the participants received a 'Living a Healthy Life with Chronic Conditions' publication with the course content outlined to serve as a guide. Six months after recruitment, all 'wait list' control patients were offered the CDSMP; of these, 72% accepted the CDSMP. Data were collected at baseline and at six months, using a questionnaire. This enabled the researchers to compare six-month outcomes in the patients allocated immediate CDSMP and those allocated 'wait list control'. Primary outcomes were 'health behaviours, health status, and health service utilisation'. The energy/ fatigue scale from the Medical Outcomes Study scale was used to measure fatigue. Then, to explore the long-term effects of CDSMP, outcome data were collected at one and two years from the participants allocated immediate CDSMP and from those 'wait list control' participants who accepted the CDSMP at six months. The purpose of this longitudinal element of the study was to describe the changes to participants from baseline, to examine the extent to which initial levels of self-efficacy and changes in selfefficacy were associated with reductions in healthcare utilisation and to describe the cost of the CDSMP intervention and potential savings due to changes in healthcare utilisation. The trial did not report results separately for the different chronic diseases (Lorig 2001). The authors of the trial provided unpublished data for the subgroup of 125 patients with stroke at the six-month follow-up, which compared outcomes between the CDSMP group and the 'wait list' control.
Ongoing studies
We identified two ongoing RCTs. The Sleep Apnoea Treatment after Stroke trial is randomising people with sleep-disordered breathing after stroke to continuous positive airways pressure (CPAP) or sham CPAP (SATS 2004) . The fatigue severity score is a secondary endpoint.
The cognitive and graded activity training trial on post-stroke fatigue (COGRAT 2008) is an ongoing multi-centre, randomised controlled trial comparing 'cognitive treatment' alone versus graded activity and cognitive treatment in patients who are at least four months post stroke and who have a fatigue score of more than 40 as measured by the Checklist for Individual Strength ( Vercoulen 1994). Ninety-six participants will be randomised. Fatigue is an outcome measure.
Excluded studies
From the PEDro search, we excluded a trial of standing practice (Allison 2007), as there were no fatigue-related outcomes. We excluded a trial of constraint-induced movement therapy ( Underwood 2006), because the intervention was not aimed at treating fatigue.
Risk of bias in included studies Allocation
Choi Kwon et al randomised patients who fulfilled the trial inclusion criteria (i.e. post-stroke emotional disturbance) using a computer-generated list of treatment numbers (Choi-Kwon 2007). The presence or severity of fatigue were not criteria for selection for the study; consequently, the placebo group contained a significantly higher number of patients with post-stroke fatigue at baseline than the treatment arm. Ogden at al stated that there was allocation concealment but details of the randomisation methods are not available (Ogden 1998). The participants in the trial by Lorig et al underwent a serial randomisation process whereby for each site, a randomisation ratio was determined to ensure that there were between 10 and 15 patients in the treatment arm (Lorig 2001) . This ratio differed between sites. Allocation concealment was not reported in the study methods.
Blinding
In one trial (Choi-Kwon 2007), participants and providers of the intervention were blinded to the treatment allocation. Fatigue was measured by self-report. In the second trial (Ogden 1998), participants, providers and outcome assessors were blinded to treatment allocation. In the third trial (Lorig 2001), the participants and providers were aware of the assigned interventions. The outcomes were reported by participants aware of their interventions by selfreported questionnaires (i.e. unblinded). Data collection from the questionnaires was conducted by people blinded to the intervention.
Intention-to-treat analysis
Choi-Kwon et al reported that intention-to-treat analysis was performed, but did not provide data on how many participants, if any, dropped out (Choi-Kwon 2007). Ogden et al did not perform intention-to-treat analysis as fatigue data could not be obtained from patients who had died, those who were deemed incapable of participating and those who did not consent (Ogden 1998). We classified this as 'an available-case analysis'. In the third trial ( Lorig 2001), six-month follow-up data were available for 104 of the subgroup of 125 stroke patients who were recruited, so we classified this as an 'available-case analysis'.
Effects of interventions
We could not perform meta-analysis as the interventions were too dissimilar. Choi-Kwon et al concluded that fluoxetine was ineffective in treating fatigue after stroke (Choi-Kwon 2007). The mean FSS in the placebo group (43 participants) and the fluoxetine group (40 participants) at baseline were 4.7 and 4.8 respectively, and the mean VAS was 6.0 and 4.8 respectively, indicating significantly higher levels of fatigue in the placebo group at baseline. At three months, the mean FSS in the placebo and fluoxetine groups were 4.3 and 3.7 respectively and the mean VAS scores were 5.3 and 4.3 respectively. At six months, the mean FSS in the placebo and fluoxetine groups were 4.2 and 3.6 respectively and mean VAS scores were 5.5 and 4.4 respectively. The percentage change in the VAS and FSS scores from baseline to follow-up assessments were not significantly different between the fluoxetine and placebo groups. It was noted that the total number of patients reporting fatigue in the fluoxetine group fell from 40 to 33 compared with 43 to 40 in the control group at three months. Ogden et al reported that only four out of nine participants in the tirilazad mesylate arm complained of debilitating fatigue at three months compared with all nine participants in the placebo arm (Ogden 1998). The difference between the two groups was statistically significant. Lorig et al demonstrated that CDSMP was a feasible intervention that was significantly better than 'wait list' control at six months in terms of health status and hospitalisations for all the 1140 patients randomised (Lorig 2001). At baseline there were 125 participants with stroke as their primary chronic condition (58 controls and 67 interventions). The mean for the 125 patients on the energyfatigue scale was 2.08 (standard deviation (SD) = 1.03) at baseline (1 to 5 range). Of the 125 patients, 104 (83%) completed sixmonth questionnaires (46 'wait list' control and 58 treatment). The mean changes scores were 0.246 (SD = 0.600) for controls and 0.087 (SD = 0.988) for treatment (i.e. fatigue became worse for 'wait list' controls but remained almost unchanged for CDSMP participants). The difference was not significant (P value 0.253).
D I S C U S S I O N
Summary of main results
To our knowledge, this is the first systematic review of interventions for fatigue after stroke. We identified only three published trials and two ongoing trials. Of the three published trials, fatigue was a secondary endpoint and the participants did not have to have fatigue to be included in the study. One trial found no difference between the effect of fluoxetine or placebo on fatigue ( Choi-Kwon 2007). The second trial found that patients with subarachnoid haemorrhage were less likely to have fatigue at three months if they had received tirilazad mesylate, but this trial was very small and more than half of the patients randomised were not available for follow up (Ogden 1998). The third trial, which recruited 1140 patients with a variety of different chronic diseases, found that a chronic disease self-management programme was no more effective in reducing fatigue than a 'wait list control' group for the subgroup of 125 people after stroke (Lorig 2001). One ongoing trial is recruiting patients who have fatigue after stroke (COGRAT 2008). The primary outcome measure is fatigue. This trial is designed to determine whether cognitive treatment plus graded activity is more effective than cognitive treatment alone. There is no 'usual care' arm in this trial, and so it will not be able to test the hypothesis that cognitive treatment is better than usual care. This hypothesis would be worth testing, because one observational study demonstrated an association between fatigue and reduced 'locus of control' (Schepers 2006). The second ongoing trial is investigating CPAP in sleep-disordered breathing and will report fatigue as a secondary endpoint. It is unlikely that CPAP would be a widely applicable treatment for fatigue after stroke, unless it was associated with sleep-disordered breathing and the patient was able to comply with treatment. Consequently, uncertainties remain about whether any of the interventions we identified might be effective for fatigue after stroke.
Overall completeness and applicability of evidence
Our review was deliberately broad and we sought to include trials in which fatigue was a secondary as well as a primary endpoint, so that the review would inform future research. The trials we identified are relevant to our review question, although the patients in the three completed trials did not have to have fatigue at baseline to be eligible for inclusion, and so the trials are not directly relevant to people presenting with fatigue after stroke. One ongoing trial is recruiting patients with fatigue after stroke and comparing graded activity plus cognitive treatment versus cognitive treatment alone (COGRAT 2008) . The studies we identified do not address all of the objectives of the review sufficiently; in particular, further research is required to test other, potentially effective interventions such as cognitive therapy, and to investigate the effect of the interventions on relevant outcomes such as health-related quality of life, costs, and risks.
Quality of evidence
We cannot draw robust conclusions as we identified only three completed studies, providing data on a total of 226 patients, and using three different interventions. There were methodological limitations with all three trials.
Potential biases in the review process
We attempted to limit bias in the review process. This review incorporated extensive literature searches guided by the Cochrane Stroke Group and we sought unpublished and ongoing work through contact with authors of included studies and other experts in the field. Two review authors independently decided whether studies should be included, and data were extracted independently by two review authors.
Agreements and disagreements with other studies and reviews
As far as we know, there are no other systematic reviews of interventions for post-stroke fatigue. We found only three trials that fulfilled our wide inclusion criteria, and these could not be combined in a meta-analysis. Our findings are consistent with previously published papers calling for more research to determine the effectiveness of interventions for post-stroke fatigue.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Currently there is insufficient evidence to guide practice in treating fatigue following stroke.
Implications for research
Given the high prevalence of fatigue following stroke, more research is urgently needed to identify treatment for this common and distressing symptom. As a first step, further work could usefully be done to explore associations of fatigue after stroke, which might provide targets for treatment. This would include systematic reviews of observational studies. Given that some studies have found an association between fatigue and mood disorders, the develop of a cognitive intervention might also be a logical step forward. 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Choi-Kwon 2007
Methods Double-blind, placebo-controlled trial of fluoxetine Presence or severity of fatigue were not used as a selection criterion for entry into the trial 
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Yes Computer-generated list of treatment numbers
Lorig 2001
Methods Randomised controlled trial Participants 1140 community-dwelling patients with diagnoses of chronic lung disease, heart disease, stroke ('completed cerebrovascular accident with neurologic handicap and normal mentation')or chronic arthritis were recruited Data for the 125 patients with stroke were provided by the authors of the trial
Interventions Chronic disease self-management programme (CDSMP) Active intervention: 7 weekly sessions each lasting 2.5 hours in community centres where patients were taught CDSMP by peer leaders. This included teaching about exercise programmes, the use of cognitive symptom management techniques, nutritional change, fatigue and sleep management, use of community resources, use of medications, dealing with emotions of fear, anger and depression, communication with others, problem solving, and decision making. The programme was implemented through a 'self-efficacy theory', the process of which was documented in a manual, and all the participants received a 'Living a Healthy Life with Chronic Conditions' publication with the course content outlined to serve as a guide Control arm: a 'wait list control'. Patients continued with usual care for 6 months and were then offered the CDSMP Outcomes Primary outcomes: 'health behaviours, health status, and health service utilisation' The energy/fatigue scale from the Medical Outcomes Study was used to measure fatigue The 6-month follow-up data from the 125 patients with stroke were provided by the authors of the trial to allow us to compare the effect of the CDSMP with the 'wait list' control 
